Literature DB >> 9549503

Status dystonicus: the syndrome and its management.

H Manji1, R S Howard, D H Miller, N P Hirsch, L Carr, K Bhatia, N Quinn, C D Marsden, K Bahtia.   

Abstract

Patients with dystonic syndromes sometimes develop increasingly frequent and relentless episodes of devastating generalized dystonia which we call status dystonicus. Twelve cases of status dystonicus, of various underlying aetiologies, are presented. Possible precipitating factors were identified in only five cases: intercurrent infection (one); discontinuation of lithium (one) and tetrabenazine (one); and the introduction of clonazepam (two). Nine patients required mechanical ventilation and three others were sedated with intravenous chlormethiazole. Drug therapy used included benzhexol, tetrabenazine, pimozide, baclofen, chlorpromazine, haloperidol, carbamazepine and acetozolamide. Two patients underwent thalamotomies, one of whom improved. Two patients died, five returned to their pre-status dystonicus condition, two eventually made a full recovery and three were worse. Patients with status dystonicus should be managed on an intensive care unit as they may develop bulbar and respiratory complications which may require ventilation. Metabolic problems encountered can include rhabdomyolysis with acute renal failure. Drug therapy with benzhexol, tetrabenazine and pimozide or haloperidol may be beneficial in some cases.

Entities:  

Mesh:

Year:  1998        PMID: 9549503     DOI: 10.1093/brain/121.2.243

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  23 in total

Review 1.  Admission to neurological intensive care: who, when, and why?

Authors:  Robin S Howard; Dimitri M Kullmann; Nicholas P Hirsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

2.  Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease.

Authors:  Chul Hyoung Lyoo; Myung Sik Lee
Journal:  J Neurol       Date:  2011-04-16       Impact factor: 4.849

Review 3.  Unusual complications of deep brain stimulation.

Authors:  Fumin Tong; Adolfo Ramirez-Zamora; Lucy Gee; Julie Pilitsis
Journal:  Neurosurg Rev       Date:  2014-10-25       Impact factor: 3.042

4.  Rhabdomyolysis. The role of diagnostic and prognostic factors.

Authors:  Eran Keltz; Fahmi Yousef Khan; Gideon Mann
Journal:  Muscles Ligaments Tendons J       Date:  2014-02-24

Review 5.  Treatment of movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

6.  Deep brain stimulation for medically refractory life-threatening status dystonicus in children.

Authors:  Brian P Walcott; Brian V Nahed; Kristopher T Kahle; Ann-Christine Duhaime; Nutan Sharma; Emad N Eskandar
Journal:  J Neurosurg Pediatr       Date:  2012-01       Impact factor: 2.375

7.  Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation.

Authors:  Alberto Benato; Miryam Carecchio; Alberto Burlina; Francesco Paoloni; Stefano Sartori; Margherita Nosadini; Domenico d'Avella; Andrea Landi; Angelo Antonini
Journal:  J Neural Transm (Vienna)       Date:  2019-05-10       Impact factor: 3.575

8.  Deep brain stimulation in critical care conditions.

Authors:  Angelo Franzini; Roberto Cordella; Michele Rizzi; Carlo E Marras; Giuseppe Messina; Giovanna Zorzi; Dario Caldiroli
Journal:  J Neural Transm (Vienna)       Date:  2013-11-30       Impact factor: 3.575

Review 9.  Identification and management of deep brain stimulation intra- and postoperative urgencies and emergencies.

Authors:  Takashi Morishita; Kelly D Foote; Adam P Burdick; Yoichi Katayama; Takamitsu Yamamoto; Steven J Frucht; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2009-11-05       Impact factor: 4.891

10.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.